Dunn Laura B, Candilis Philip J, Roberts Laura Weiss
Department of Psychiatry, University of California, San Diego, USA.
Schizophr Bull. 2006 Jan;32(1):47-68. doi: 10.1093/schbul/sbj012. Epub 2005 Oct 19.
Many challenging ethical questions come with the scientific efforts to understand the nature and treatment of schizophrenia. The empirical study of ethical aspects of schizophrenia research has sought to clarify and resolve many of these questions. In this article we provide an overview of the existing data-based literature on schizophrenia research ethics and outline directions for future inquiry. We examine 5 broad categories of inquiry into the ethics of schizophrenia research: (1) Scientific designs (eg, placebo-controlled studies and medication-free intervals, prodromal and high-risk research, and genetics research); (2) informed consent and decision-making capacity, including assessment of decisional abilities, as well as intervention studies; (3) understanding and perceptions of risk and benefit (including the therapeutic misconception); (4) influences on research participation (including voluntarism, altruism, and other motivations); and (5) key participant safeguards, such as protocol review and participant advocates. We discuss how empirical work in each of these areas answers certain questions and raises new ones. Finally, we highlight important gaps in our understanding of ethically relevant aspects of schizophrenia research and offer a specific research agenda for empirical ethics.
在理解精神分裂症的本质和治疗方法的科学研究过程中,出现了许多具有挑战性的伦理问题。对精神分裂症研究伦理方面的实证研究试图阐明并解决其中的许多问题。在本文中,我们概述了现有的关于精神分裂症研究伦理的基于数据的文献,并概述了未来研究的方向。我们审视了对精神分裂症研究伦理的五大类探究:(1)科学设计(例如,安慰剂对照研究和无药间隔期、前驱期和高危研究以及遗传学研究);(2)知情同意和决策能力,包括决策能力评估以及干预研究;(3)对风险和益处的理解与认知(包括治疗误解);(4)对研究参与的影响(包括自愿性、利他主义及其他动机);以及(5)关键的参与者保障措施,如方案审查和参与者倡导者。我们讨论了这些领域中的实证工作如何回答某些问题并提出新问题。最后,我们强调了在理解精神分裂症研究伦理相关方面存在的重要差距,并为实证伦理学提供了一个具体的研究议程。